Earlier this year, hundreds of advocates representing every state gathered in Washington, DC for the Rare Disease Week Legislative Conference. Their energy and enthusiasm raised the roof, as they shared experiences and prepared to visit their legislators on Capitol Hill.
At a time of divided politics and diverse opinions, easing the burden of rare diseases is emerging as a cause that everyone can understand and support.
When pharma treats patients as partners, it’s much easier to reach our shared goal of better health. In our final J.P. Morgan blog post, Chris Smith weighs in.
Time has run short for taking a comprehensive look at one of the most difficult topics in the industry—how best to regulate compassion.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Chris Smith flips the script on David for his thoughts, and David talks about the challenges of estimating a treatable population.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Chris Smith shares how our understanding of rare disease is evolving, and why it may be a misleading term.